| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5878229 | Journal of Pain and Symptom Management | 2009 | 7 Pages |
Abstract
Off-label prescription is part of routine care in palliative medicine, but no information is available about the situation in Italy. A cross-sectional observational survey was undertaken on all 66 Italian palliative care freestanding inpatient units to describe off-label prescriptions. Data were collected on 507 patients. Each prescribed drug was matched with Italian Marketing Authorization indications: 159 drugs off-label (4.5% of all prescribed drugs) for the stated indication were given to 128 patients (25.2%), and drugs unlicensed for subcutaneous injection were given to 147 patients (85.4% of all subcutaneous prescriptions, excluding insulin and heparin). The off-label prescriptions were subsequently evaluated by referring to the Italian National Pharmaceutical Formulary (INPF) and the British Palliative Care Formulary (PCF2). Although drugs are frequently prescribed off-label in inpatient palliative care units in Italy, this strategy was not always backed by clinical evidence, and in some cases, official/authoritative sources, such as INPF and PCF2 did not support it. Clinical trials and/or agreed international guidelines are needed to support the off-label use of the most widely prescribed drugs in palliation.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Franco MD, Paola RN, MSC, Rita ScD, Ivanoe MD, Anna MD, Giuseppe MD, End of Life Observatory Research Group End of Life Observatory Research Group,
